Summary & Overview
HCPCS Q5123: Injection, rituximab-arrx (riabni), 10 mg
HCPCS Level II code Q5123 designates a 10 mg unit of rituximab-arrx (riabni), a biosimilar to rituximab used for infusion therapy. This code matters nationally because biosimilar oncology and immunology agents are increasingly used to reduce drug costs while maintaining clinical access; accurate coding of biosimilars affects billing, reimbursement, and utilization reporting across payers. Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find: concise benchmarks and payer coverage context for biosimilar rituximab dosing units; an explanation of the clinical and service context for infusion administration; and a summary of coding considerations relevant to billing of biosimilar monoclonal antibodies. The publication addresses typical sites of service where Q5123-coded product is administered, and outlines what data is available versus not provided in the input. This executive summary is intended to inform coding professionals, revenue cycle leaders, and policy analysts about the role of HCPCS Level II code Q5123 in national billing practices and payer coverage landscapes.
Billing Code Overview
HCPCS Level II code Q5123 represents an injection of rituximab-arrx, a biosimilar to rituximab marketed as riabni, in a 10 mg unit. The code describes the drug product and unit of measure for administration of this monoclonal antibody.
Service Type: Drug administration / infused biologic agent
Typical Site of Service: Infusion center, outpatient hospital infusion suite, or clinic-based infusion setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a B‑cell mediated hematologic or autoimmune condition (for example, diffuse large B‑cell lymphoma or rheumatoid arthritis) receiving intravenous infusion of the rituximab biosimilar Q5123 (rituximab-arrx, riabni) dosed per 10 mg units. The clinical workflow begins with an outpatient oncology or infusion center visit where the patient is assessed by an oncology or rheumatology nurse and clinician for indication, baseline vitals, allergy history, and premedication needs (acetaminophen, antihistamine, corticosteroid). A pharmacist prepares the calculated dose from Q5123 units, and the patient is connected to an IV infusion pump. During infusion, nursing documents vital signs, infusion rate adjustments, and any infusion reactions. After completion, the nurse documents total administered dose, waste if applicable (for JW or JZ modifier contexts), and provides post‑infusion monitoring instructions. Typical sites of service are outpatient hospital infusion centers, physician office infusion suites, and specialty infusion clinics. The procedure is performed by infusion nurses under physician order with medication billing under the HCPCS Level II code Q5123 for the biosimilar product.
Coding Specifications
| Modifier | Description | When to Use |
|---|